论文部分内容阅读
目的通过Meta分析的方法综合评价CD133与肺癌患者临床病理特征关系。方法计算机检索Pubmed、Embase和CNKI,纳入公开发表涉及CD133表达与肺癌临床病理特征的中英文文献,使用Stata 12.0统计学软件对符合条件的文献进行分析。结果共获取文献15篇(英文7篇、中文8篇),1102例患者。Meta分析结果CD133表达在临床分期Ⅰ、Ⅱ期与Ⅲ期之间无显著性差异(pooled OR=0.782,95%CI=0.435~1.406,P=0.411)。CD133表达在腺癌与非腺癌之间无显著性差异(pooled OR=0.97,95%CI=0.71~1.33,P=0.86)。CD133表达在肺癌低分化与高分化差异有统计学意义(pooled OR=1.66,95%CI=1.15~2.40,P=0.006);CD133表达在肺癌淋巴结转移与非淋巴结转移差异有统计学意义(pooled OR=2.98,95%CI=2.04~4.35,P<0.001)。结论 CD133阳性与肺癌组织低分化相关,且发生淋巴结转移可能性高。
Objective To evaluate the relationship between CD133 and clinicopathological features of lung cancer patients by Meta-analysis. METHODS: Pubmed, Embase and CNKI were searched by computer. The articles published both in Chinese and English, which relate to the clinicopathological features of CD133 and lung cancer, were analyzed using Stata 12.0 statistical software. Results A total of 15 articles were obtained (7 in English, 8 in Chinese) and 1,102 in the study. Meta analysis showed no significant difference in the expression of CD133 between clinical stages I, II and III (pooled OR = 0.782, 95% CI = 0.435 ~ 1.406, P = 0.411). There was no significant difference in CD133 expression between adenocarcinoma and non-adenocarcinoma (pooled OR = 0.97, 95% CI = 0.71-1.33, P = 0.86). CD133 expression was significantly different between poorly differentiated and well-differentiated lung cancer (pooled OR = 1.66, 95% CI = 1.15-2.40, P = 0.006); CD133 expression was significantly different between lymph node metastasis and non-lymph node metastasis in lung cancer (pooled OR = 2.98, 95% CI = 2.04 to 4.35, P <0.001). Conclusion The positive expression of CD133 is associated with poorly differentiated lung cancer and the possibility of lymph node metastasis.